Raymond James, a well-respected financial institution, has initiated coverage on Fusion Pharmaceuticals with an Outperform rating and a price target of $13. This positive rating from a reputable analyst is likely to boost investor confidence in FUSN and may lead to an increase in its stock price in the short term.